The therapeutic range for efavirenz plasma concentrations is unclear and some studies
found no correlation with viral non-suppression. Efavirenz concentrations are variable …

We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by
enrolling 456 HIV-positive patients who had received 2 nucleos (t) ide reverse-transcriptase …

Background. Efavirenz has a long plasma half-life and a low genetic barrier to resistance.
Simultaneously stopping treatment with all agents in efavirenz-containing regimens may …

Objectives Efavirenz is widely prescribed for HIV-1 infection, and CYP2B6 polymorphisms
516G→ T and 983T→ C define efavirenz slow metabolizer genotypes. To identify genetic …

Aim: We investigated the effects of rifampicin-based anti-TB treatment on plasma efavirenz
exposure and the implications of CYP2B6 genotype. Patients & methods: Antiretroviral …

Objectives Efavirenz is widely prescribed for HIV-1 infection. Three polymorphisms in
CYP2B6 define plasma efavirenz trough concentration strata that vary across an∼ 10-fold …

Abstract Background Polymorphisms in CYP2B6 are known to predict increased steady-
state plasma concentrations of efavirenz. We characterized relationships between genetic …

We investigated the influence of gender and pharmacogenetic variations on long‐term
efavirenz autoinduction and disposition among patients with HIV in Tanzania (N= 129) …

Background: CYP2B6 polymorphisms that affect efavirenz (EFV) concentrations are
common, but the effect of this polymorphism on HIV virologic failure in clinical practice …

Objective: UDP-glucuronosyltransferase (UGT) 2B7 was recently identified as the main
enzyme mediating efavirenz N-glucuronidation. In this study, we determined whether …